TBPH Theravance Biopharma
- 9.320
- -0.150-1.58%
Theravance Biopharma News
Theravance Biopharma to Participate in an Upcoming Investor Conference
Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at...
Strong Week for Theravance Biopharma (NASDAQ:TBPH) Shareholders Doesn't Alleviate Pain of Five-year Loss
Theravance Biopharma, Inc. (NASDAQ:TBPH) shareholders should be happy to see the share price up 13% in the last week. But don't envy holders -- looking back over 5 years the returns have been reall
Theravance Biopharma(TBPH.US) 10% Shareholder Buys US$13.12 Million in Common Stock
$Theravance Biopharma(TBPH.US)$ 10% Shareholder Samaha Eli purchased 1.5 million shares of common stock on May 1, 2024 at an average price of $8.75 for a total value of $13.12 million.Source: Announce
Theravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024
DUBLIN, April 29, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its first quarter 2024 financial results and provide a business update after market close on Monday, May 1
Sector Update: Health Care Stocks Lower Friday Afternoon
Health care stocks were retreating Friday afternoon, with the NYSE Health Care Index falling 1.5% and the Health Care Select Sector SPDR Fund (XLV) dropping 1.6%. The iShares Biotechnology ETF (IBB) w
Theravance Biopharma Shares Rise After BTIG Starts Coverage at Buy
Theravance Biopharma (TBPH) shares climbed 8.3% in recent Friday trading after BTIG started its coverage with a buy rating and a price target of $21. Trading volume stood at more than 330,000 shares a
Veru, Theravance Biopharma, Adial Pharmaceuticals Among Healthcare Movers
Theravance Biopharma (TBPH.US) was first covered by BTIG and given a buy rating, with a target price of $21.00.
Theravance Biopharma (TBPH.US) was first covered by BTIG and given a buy rating, with a target price of $21.00.
BTIG Initiates Coverage On Theravance Biopharma With Buy Rating, Announces Price Target of $21
BTIG analyst Julian Harrison initiates coverage on Theravance Biopharma with a Buy rating and announces Price Target of $21.
Theravance Biopharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/12/2024 135.16% BTIG → $21 Initiates Coverage On → Buy 08/08/2023 123.96% HC Wainwright & Co. → $20 Rei
Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (NOH) in Patients With Multiple System Atrophy (MSA) on May 23, 2024
Theravance Biopharma, Inc. (the "Company") (NASDAQ: TBPH) today announced it will host a virtual KOL event on Thursday, May 23, 2024 from 10:00 AM to ...
Nektar (NKTR) Up 7.5% Since Last Earnings Report: Can It Continue?
A New Cause for Concern: Theravance Biopharma Adds a New Costs Risk
Theravance Biopharma: A Strong Buy on Underappreciated Cash Flow Potential and Strategic Milestones
Theravance Biopharma: A Strong Buy on Robust Yupelri Sales and Promising Financial Milestones
Earnings Call Summary | Theravance Biopharma(TBPH.US) Q4 2023 Earnings Conference
The following is a summary of the Theravance Biopharma, Inc. (TBPH) Q4 2023 Earnings Call Transcript:Financial Performance:YUPELRI's net sales growth for the full year of 2023 was 9%, achieving $221 m
Balancing Growth Prospects and Clinical Outcomes: Hold Rating on Theravance Biopharma
Theravance Biopharma Expects Non-GAAP Loss In H1 Of 2024 And Approach Non-GAAP Breakeven In H2 Of 2024; Limited Cash Burn Expected In 2024
Theravance Biopharma Expects Non-GAAP Loss In H1 Of 2024 And Approach Non-GAAP Breakeven In H2 Of 2024; Limited Cash Burn Expected In 2024
Earnings Flash (TBPH) THERAVANCE BIOPHARMA Posts Q4 Revenue $17.6M, Vs. Street Est of $17.6M
04:09 PM EST, 02/26/2024 (MT Newswires) -- Earnings Flash (TBPH) THERAVANCE BIOPHARMA Posts Q4 Revenue $17.6M, vs. Street Est of $17.6M
Theravance Biopharma Q4 2023 GAAP EPS $(0.17) Misses $(0.15) Estimate, Sales $17.57M Miss $17.68M Estimate
Theravance Biopharma (NASDAQ:TBPH) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.15) by 13.33 percent. The company reported quarterly sales of $17.
Analysis
Price Target
No Data
